[VIRTUAL] Durvalumab ± Tremelimumab + Chemotherapy as First - line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

[VIRTUAL] First - line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

[VIRTUAL] A Phase II Study of Frontline Rucaparib + Nivolumab in Platinum Sensitive ES SCLC: Interim Analysis

[VIRTUAL] Neoadjuvant Pembrolizumab for Early Stage Non - Small Cell Lung Cancer

[VIRTUAL] A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor (KCSG LU17 - 21)

[VIRTUAL] EPICAL Trial. A Phase Ib StudyCombining Anti - Epidermal Growth Factor (EGF) Vaccination With Afatinib in EGFR - Mutant Non - Small Cell Lung Cancer

[VIRTUAL] TROPION - PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors

[VIRTUAL] Phase II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Recurrent Non - Small Cell Lung Cancer

[VIRTUAL] Body Mass Index Predicts Benefit From Adding Metformin to EGFR - TKIs in Patients With Lung Adenocarcinoma: Subanalysis From an RCT

[VIRTUAL] Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non - Squamous Non - Small Cell Lung Cancer in IMpower150

[VIRTUAL] Inferior Outcomes in Minority Patients with Unresectable Non - Small Cell Lung Cancer (NSCLC) After Durvalumab Consolidation Therapy

[VIRTUAL] Phase 1b Study of Pelcitoclax (APG - 1252) in Combination With Osimertinib in Patients With EGFR TKI - Resistant NSCLC

[VIRTUAL] Effects of the Immunotherapy Era on Maintenance Outcomes in Advanced Nonsquamous NSCLC: Subgroup Analysis of ECOG 5508

[VIRTUAL] T - DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm+ NSCLC: Interim Analysis of a Phase II Trial